enow.com Web Search

  1. Ad

    related to: drugs that increase gi motility in men and prostate cancer

Search results

  1. Results from the WOW.Com Content Network
  2. Prokinetic agent - Wikipedia

    en.wikipedia.org/wiki/Prokinetic_agent

    Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...

  3. List of antineoplastic agents - Wikipedia

    en.wikipedia.org/wiki/List_of_antineoplastic_agents

    Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.

  4. Androgen deprivation therapy - Wikipedia

    en.wikipedia.org/wiki/Androgen_deprivation_therapy

    Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

  5. Bethanechol - Wikipedia

    en.wikipedia.org/wiki/Bethanechol

    The muscarinic receptors in the bladder and gastrointestinal tract stimulate contraction of the bladder and expulsion of urine, and increased gastrointestinal motility, respectively. Bethanechol should be used to treat these disorders only after mechanical obstruction is ruled out as a possible cause.

  6. Dutasteride - Wikipedia

    en.wikipedia.org/wiki/Dutasteride

    The American Urological Association advises that increased risk for patients taking these drugs leads to higher prostate cancer-specific and all-cause mortality. [30] The AUA also advises that this affect can be alleviated with more frequent screening and lower PSA cutoffs for diagnostic biopsies in men taking dutasteride or other 5α-reductase ...

  7. Mosapride - Wikipedia

    en.wikipedia.org/wiki/Mosapride

    Mosapride is a gastroprokinetic agent that acts as a selective 5HT 4 agonist.The major active metabolite of mosapride, known as M1, additionally acts as a 5HT 3 antagonist, [1] which accelerates emptying throughout the whole of the gastrointestinal tract in humans, [2] and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia [3] and irritable bowel ...

  8. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    Antiandrogens are medications such as flutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, and cyproterone acetate that directly block the actions of testosterone and DHT within prostate cancer cells. In men with metastatic, hormone-sensitive prostate cancer, doctors may recommend adding taxane-based chemotherapy to hormone therapy. [45]

  9. Abiraterone acetate - Wikipedia

    en.wikipedia.org/wiki/Abiraterone_acetate

    Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [2] [6] [5] [4] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.

  1. Ad

    related to: drugs that increase gi motility in men and prostate cancer